Indications
Iqirvo is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
Composition
- Active substance
- Elafibranor
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Iqirvo
- Active substance
- Elafibranor
- ATC code
- A05AX06
- Therapeutic area
- Liver Cirrhosis, Biliary
- Marketing authorisation holder
- Ipsen Pharma
- Status
- Authorised